“Calder Biosciences is exploring a new era in vaccines by developing a 3D shape-stabilizing
technology that locks vaccine immunogens in the same structure found on pathogens, enhancing
immune protection. By preserving the correct shape for longer, our process improves antibody
recognition and binding — boosting potency, efficacy and safety. “When we started working with
Phil in 2017, we were still under a previous company, whose activities included work in industrial
enzymes and protein chips. As we moved into vaccines, he believed it was best to start from the
ground up with a new company. He created an asset transfer agreement, formed Calder and
coordinated the operational paperwork needed to move us from an LLC to a C corporation. Since
then, we’ve received millions in grants and additional millions in venture financing. Moving
forward, we’re working to secure strategic and investment partners to participate in a round of
venture funding that will allow us to complete clinical manufacturing of our lead program, run a
Ph1 study, and ultimately bring to the marketplace. “Phil devised a truly elegant legal framework
to transfer the assets, and we’ve been very impressed by his services, background and expertise.
We’ve previously worked with larger firms, but Crowley Law LLC’s capabilities and greater
availability were a much better fit for our company.”